New Technology Is Transforming Type 2 Diabetes Care—Here's What You Need to Know

Revolutionary diabetes technology is delivering life-changing results for people with type 2 diabetes, with new studies showing automated insulin delivery systems and continuous glucose monitoring (CGM) can significantly improve blood sugar control and quality of life. Recent breakthrough research demonstrates these advanced tools are no longer just for type 1 diabetes—they're transforming care for the 37 million Americans living with type 2 diabetes.

How Effective Are Automated Insulin Delivery Systems?

The SECURE-T2D pivotal trial tested the Omnipod 5 automated insulin delivery (AID) system in 305 adults with type 2 diabetes, representing the first large-scale study of this tubeless insulin pump technology. The results were remarkable: participants saw their A1C levels drop from an average of 8.2% to 7.4% after just 13 weeks of use—a significant 0.8% reduction.

"The results from the SECURE-T2D trial underscore the potential of the Omnipod 5 AID System to transform diabetes management for adults with type 2 diabetes," said Francisco J. Pasquel, MD, MPH, Associate Professor of Medicine and Global Health at Emory University, and lead author of the study. "The substantial improvements in glycemic control and quality of life, particularly among minority populations, are promising steps toward more equitable diabetes care."

The study was notably diverse, including 24% Black and 22% Hispanic/Latino participants—populations that often face greater challenges in diabetes management. The automated system works by continuously monitoring glucose levels and adjusting insulin delivery in real-time, reducing the burden of manual insulin dosing.

What Makes Continuous Glucose Monitoring So Powerful?

Continuous glucose monitoring is proving beneficial far beyond its traditional use in type 1 diabetes. A massive real-world analysis of over 7.1 million type 2 diabetes patients found that CGM use led to substantial improvements across all treatment types, with A1C levels dropping by 1% across all therapy groups after 12 months.

The 2026 American Diabetes Association Standards of Care now recommends CGM use at diabetes onset and anytime thereafter for anyone who could benefit, marking a significant shift in diabetes care guidelines. This expanded recommendation includes:

• Type 2 Diabetes Patients Not Using Insulin: A study of over 3,800 adults using Dexcom sensors showed a 0.5% reduction in glucose management indicator and 17% increase in time in range—equivalent to four additional hours per day in target glucose levels
• Older Adults at Higher Risk: The technology helps prevent dangerous low blood sugar episodes while maintaining better overall glucose control
• Patients with Gestational Diabetes: CGM provides crucial glucose stability during pregnancy for better maternal and fetal outcomes

Perhaps most impressive, CGM use resulted in more than a 50% reduction in all-cause hospitalizations and acute diabetes-related hospitalizations, demonstrating significant healthcare cost savings.

How Are Treatment Guidelines Changing?

The 2026 Standards of Care represents a major shift toward technology-forward, patient-centered diabetes care. The guidelines now remove previous requirements that patients had to meet before starting continuous subcutaneous insulin infusion or automated insulin delivery systems, making these life-changing technologies more accessible.

"The SOC bridges the evidence-to-practice gap that has continued to stymie progress in diabetes management and outcomes," said Rozalina McCoy, MD, MS, associate professor of medicine at the University of Maryland School of Medicine and co-chair of the ADA Professional Practice Committee for Diabetes.

The updated guidelines also emphasize using glucose-lowering medications like glucagon-like peptide-1 receptor agonists (GLP-1s) to treat multiple conditions simultaneously, including diabetes, obesity, and cardiovascular disease. This comprehensive approach recognizes that people with diabetes often have multiple health concerns that can be addressed with coordinated treatment strategies.

These technological advances represent a fundamental shift in diabetes care, moving from reactive management to proactive, personalized treatment that can prevent complications before they occur. For the millions of Americans living with type 2 diabetes, these innovations offer hope for better health outcomes and improved quality of life.